



(51) International Patent Classification:

A61K 31/513 (2006.01) A61P 3/04 (2006.01)
A61K 45/06 (2006.01) A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2025/015378

(22) International Filing Date:

11 February 2025 (11.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/552,495 12 February 2024 (12.02.2024) US
63/650,226 21 May 2024 (21.05.2024) US

(71) Applicant: **CORCEPT THERAPEUTICS INCORPORATED** [US/US]; 101 Redwood Shores Parkway, Redwood City, California 94065 (US).

(72) Inventors: **CUSTODIO, Joseph**; c/o Corcept Therapeutics Incorporated, 101 Redwood Shores Parkway, Redwood City, California 94065 (US). **KUNTA, Jeevan**; c/o Corcept Therapeutics Incorporated, 101 Redwood Shores Parkway, Redwood City, California 94065 (US). **HUNT, Hazel**; c/

o Corcept Therapeutics Incorporated, 101 Redwood Shores Parkway, Redwood City, California 94065 (US).

(74) Agent: **GAO, Chuan** et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: CONCOMITANT ADMINISTRATION OF MIRICORILANT WITH CYP2C19 INHIBITORS




FIG. 2

(57) Abstract: Miricorilant is a cyclohexyl pyrimidine compound useful for treating fatty liver diseases. Miricorilant was well tolerated in patients and healthy volunteers, and may be safely co-administered with a strong CYP2C19 inhibitor without modification of the miricorilant dose, allowing safe administration of both drugs. These results indicate that administration of miricorilant provides safe and improved methods of treating patients suffering from fatty liver diseases.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*